NovaBridge Biosciences (NBP) Capital Expenditures (2019 - 2024)

NovaBridge Biosciences (NBP) posted quarterly Capital Expenditures of -$38000.0 for Q4 2024, down 3700.0% on a QoQ basis from -$1000.0 in Q3 2024.

NovaBridge Biosciences (NBP) Capital Expenditures (2019 - 2024) Analysis & Trends

NovaBridge Biosciences (NBP) has reported Capital Expenditures for 3 consecutive years, with -$38000.0 the latest figure, recorded in Q4 2024.

Quarterly Capital Expenditures changed N/A year-over-year to -$38000.0 in Q4 2024, while the trailing twelve-month figure through Dec 2025 was -$39000.0 (down 103.2% YoY) and the FY2025 annual result came in at -$7000.0, up 85.42% from the prior year.
Capital Expenditures slipped to -$38000.0 in Q4 2024 per NBP's latest filing, from -$1000.0 in the prior quarter.
Over the last five years, Capital Expenditures for NBP reached as high as $1.9 million in Q4 2020 and fell as low as -$668360.0 in Q3 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Capital Expenditures (Qtr)
1	Oculis Holding AG	66,621.14 Bn	66,620.85 Bn	-	-8,939.03
2	Nanobiotix	1,915.18 Bn	1,915.11 Bn	-	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-	-
4	BeOne Medicines	471.27 Bn	466.48 Bn	1.35 Bn	43.25 Mn
5	Vertex Pharmaceuticals	121.81 Bn	114.57 Bn	2.59 Bn	133.40 Mn
6	Regeneron Pharmaceuticals	69.58 Bn	60.82 Bn	3.31 Bn	230.60 Mn
7	Belite Bio	62.72 Bn	62.72 Bn	-	-
8	Argenx Se	55.51 Bn	50.33 Bn	1.41 Bn	-
9	Revolution Medicines	37.35 Bn	37.35 Bn	-	786,000.00
10	NovaBridge Biosciences	397.57 Mn	397.57 Mn	-	-

Download Data